Teva Voids Novartis' European Patent Over Cancer Drug
An appeals board has stripped Novartis of its European patent over a cancer drug following a challenge from Teva, ruling in a decision published Monday that the treatment isn't inventive....To view the full article, register now.
Already a subscriber? Click here to view full article